The new patent for Exparel is a significant development as it delays generic competition, which is crucial for maintaining market share. Additionally, the launch of Vertex's Journavx could increase market awareness for non-opioid pain relief, indirectly benefiting Exparel. These factors contribute to the positive stock movement.